Susceptibility to neuroleptic-induced parkinsonism - age and increased substantia nigra echogenicity as putative risk factors

被引:30
作者
Jabs, BE
Bartsch, AJ
Pfuhlmann, B
机构
[1] Univ Wurzburg, Dept Psychiat, D-97080 Wurzburg, Germany
[2] Univ Wurzburg, Div Neuroradiol, D-97080 Wurzburg, Germany
关键词
antipsychotic agents; adverse effects; secondary Parkinson's disease; transcranial ultrasonography; substantia nigra;
D O I
10.1016/S0924-9338(03)00045-2
中图分类号
R749 [精神病学];
学科分类号
100205 [精神病与精神卫生学];
摘要
Objective. - Patients treated by neuroleptics often develop neuroleptic-induced parkinsonism (NIP) to a varying extent. The reasons for this are discussed controversially in the literature. Previous transcranial sonography (TCS) findings of the substantia nigra (SN) in patients with idiopathic Parkinson's disease suggest a correlation of echogenicity with nigrostriatal dysfunction. Method. - One hundred psychiatric patients receiving neuroleptics were included. They underwent clinical examination for NIP (Simpson and An us-scale) and, independently, TCS of the SN. History of smoking habits and medication were taken from the patient's chart. Results. - We found a significant positive association of the prevalence of NIP with age (P < 0.01) and the echogenic area of the SN (P < 0.05). Neither type nor dosage of the neuroleptics was found to have any significant impact on the occurrence of NIP. Smokers displayed lower prevalence of NIP (P < 0.05) and lower EPS scores (P < 0.0 1). Conclusions. - These findings suggest that age and increased size of SN echogenicity are possible risk factors for NIP. In contrast, smoking seems to have a certain protecting effect. 41 (C) 2003 Editions scientifiques et medicales Elsevier SAS. All rights reserved.
引用
收藏
页码:177 / 181
页数:5
相关论文
共 30 条
[1]
CENTRAL ACTIONS OF NICOTINE [J].
ACETO, MD ;
MARTIN, BR .
MEDICINAL RESEARCH REVIEWS, 1982, 2 (01) :43-62
[2]
Smoking and psychiatric illness: Mechanisms and interventions [J].
Batra, A .
FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2000, 68 (02) :80-92
[3]
DEGENERATION OF SUBSTANTIA-NIGRA IN CHRONIC PARKINSONS-DISEASE VISUALIZED BY TRANSCRANIAL COLOR-CODED REAL-TIME SONOGRAPHY [J].
BECKER, G ;
SEUFERT, J ;
BOGDAHN, U ;
REICHMANN, H ;
REINERS, K .
NEUROLOGY, 1995, 45 (01) :182-184
[4]
Vulnerability of the nigrostriatal system as detected by transcranial ultrasound [J].
Berg, D ;
Becker, G ;
Zeiler, B ;
Tucha, O ;
Hofmann, E ;
Preier, M ;
Benz, P ;
Jost, W ;
Reiners, K ;
Lange, KW .
NEUROLOGY, 1999, 53 (05) :1026-1031
[5]
NIGRAL DYSFUNCTION IN DRUG-INDUCED PARKINSONISM - AN F-18 DOPA PET STUDY [J].
BURN, DJ ;
BROOKS, DJ .
NEUROLOGY, 1993, 43 (03) :552-556
[6]
Caligiuri MP, 1997, J NEUROPSYCH CLIN N, V9, P562
[7]
CIGARETTE-SMOKING AND NEUROLEPTIC-INDUCED PARKINSONISM [J].
DECINA, P ;
CARACCI, G ;
SANDIK, R ;
BERMAN, W ;
MUKHERJEE, S ;
SCAPICCHIO, P .
BIOLOGICAL PSYCHIATRY, 1990, 28 (06) :502-508
[8]
ERESHEFSKY L, 1991, J CLIN PSYCHOPHARM, V11, P296
[9]
FARDE L, 1988, ARCH GEN PSYCHIAT, V45, P71
[10]
Neuropharmacological actions of cigarette smoke: Brain monoamine oxidase B (MAO B) inhibition [J].
Fowler, JS ;
Volkow, ND ;
Wang, GJ ;
Pappas, N ;
Logan, J ;
MacGregor, R ;
Alexoff, D ;
Wolf, AP ;
Warner, D ;
Cilento, R ;
Zezulkova, I .
JOURNAL OF ADDICTIVE DISEASES, 1998, 17 (01) :23-34